Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	35.4B	31.6B	28.0B	22.8B	21.3B
Cost of Revenue	4.9B	4.4B	3.8B	3.5B	3.5B
Gross Profit	30.5B	27.3B	24.1B	19.3B	17.8B
Operating Expenses
R&D Expense	7.9B	7.0B	6.6B	5.0B	4.9B
SG&A Expense	6.6B	—	—	—	—
General & Admin Expense	1.3B	2.8B	2.6B	2.4B	2.3B
Selling & Marketing Expense	4.5B	9.1B	8.3B	7.6B	7.3B
Other Expenses	285.4M	—	—	—	—
Total Operating Expenses	20.7B	18.7B	17.2B	14.7B	14.3B
Cost and Expenses	25.6B	23.1B	21.0B	18.2B	17.7B
Operating Income (EBIT)	10.1B	9.0B	7.5B	4.9B	4.1B
Non-Operating
Interest Income	835.9M	—	—	—	—
Interest Expense	4.1M	—	—	—	—
Net Interest Income	831.8M	—	—	—	—
Other Non-Op Income/Expense	884.8M	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	10.8B	8.7B	7.2B	4.7B	4.0B
Income Tax Expense	1.2B	990.6M	832.7M	389.3M	153.4M
Bottom Line
Net Income	9.6B	7.7B	6.3B	4.3B	3.9B
Earnings from Cont. Ops	9.6B	7.7B	6.3B	4.3B	3.8B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	9.6B	7.7B	6.3B	4.3B	3.9B
Per Share
Basic EPS	CN¥1.45	CN¥1.19	CN¥1.00	CN¥0.68	CN¥0.61
Diluted EPS	CN¥1.45	CN¥1.18	CN¥1.00	CN¥0.68	CN¥0.61
Revenue Per Share	CN¥5.37	CN¥4.88	CN¥4.42	CN¥3.61	CN¥3.32
Shares
Basic Shares Outstanding	6.6B	6.5B	6.3B	6.3B	6.4B
Diluted Shares Outstanding	6.6B	6.5B	6.3B	6.3B	6.4B
Profitability Metrics
EBITDA	5.4B	9.9B	8.3B	5.7B	4.7B
D&A	308.2M	901.5M	817.1M	755.8M	605.4M
EBIT	5.1B	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026